(Q38178187)

30 August 2017

title

Prognostic and predictive biomarkers in lung cancer. A review (English)

1 reference

30 August 2017

0 references

1

Erik Thunnissen

1 reference

30 August 2017

author name string

Kimberly van der Oord

series ordinal

2

1 reference

30 August 2017

Michael den Bakker

series ordinal

3

1 reference

30 August 2017

publication date

14 January 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

464

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

347-358

1 reference

The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Molecular and biological factors in the prognosis of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Genomic landscape of non-small cell lung cancer in smokers and never-smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by α1 nicotinic acetylcholine receptor-mediated activation in PC9 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

MET as a possible target for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

New targetable oncogenes in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Characteristics of lung cancers harboring NRAS mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

KRAS mutations as prognostic and predictive markers in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Lung cancer: intragenic ERBB2 kinase mutations in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

KIF5B-RET fusions in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

RET, ROS1 and ALK fusions in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

The transcriptional landscape and mutational profile of lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

A patient with lung adenocarcinoma and RET fusion treated with vandetanib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

ROS1 fusions in Chinese patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

The introduction of systematic genomic testing for patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

FGFR1 amplification in squamous cell carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

FGFR1 expression and gene copy numbers in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Prognostic Value of Fibroblast Growth Factor Receptor 1 Gene Locus Amplification in Resected Lung Squamous Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Disseminated mediastinal carcinoma with chromosomal translocation (15;19). A distinctive clinicopathologic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Pathologic characteristics of NUT midline carcinoma arising in the mediastinum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Clinicopathologic features and long-term outcomes of NUT midline carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Differentiation of NUT midline carcinoma by epigenomic reprogramming

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

11q21 rearrangement is a frequent and highly specific genetic alteration in mucoepidermoid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Fusion oncogenes in salivary gland tumors: molecular and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

PTEN expression in non–small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1535-4

PIK3CA mutation status in Japanese lung cancer patients

21 January 2018

1 reference

12 December 2020

Intrathoracic Carcinoma in an 11-Year-Old Girl Showing a Translocation t(15;19)

1 reference

12 December 2020

Mammary analogue secretory carcinoma of the salivary glands with ETV6-NTRK3 gene fusion

1 reference

12 December 2020

Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma

1 reference

12 December 2020

Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center

1 reference

12 December 2020

CRTC1-MAML2 gene fusion in mucoepidermoid carcinoma of the lacrimal gland

1 reference

12 December 2020

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

1 reference

12 December 2020

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas

1 reference

12 December 2020

Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma.

1 reference

12 December 2020

The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data.

1 reference

12 December 2020

EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice

1 reference

12 December 2020

PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients

1 reference

12 December 2020

Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1.

1 reference

12 December 2020

Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer

1 reference

12 December 2020

PIK3CA mutation in Chinese patients with lung squamous cell carcinoma

1 reference

12 December 2020

High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer.

1 reference

12 December 2020

Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent

1 reference

12 December 2020

Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma

1 reference

12 December 2020

Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification

1 reference

12 December 2020

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

12 December 2020

A study of ΔNp63 expression in lung non-small cell carcinomas

1 reference

12 December 2020

CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma

1 reference

12 December 2020

Small-cell lung cancer

1 reference

12 December 2020

Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis

1 reference

12 December 2020

Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo

1 reference

12 December 2020

Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC).

1 reference

12 December 2020

PIK3CA gene amplification in Japanese non-small cell lung cancer

1 reference

12 December 2020

PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma

1 reference

12 December 2020

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

12 December 2020

Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.

1 reference

12 December 2020

Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity.

1 reference

12 December 2020

10.1007/S00428-014-1535-4

Identifiers

DOI

1 reference

30 August 2017

1 reference